Therapeutics for solid tumors remain in a nascent corner of cancer research despite representing 90% of all cancers in adults. Thirty years after the first Chimeric Antigen Receptor was reported, CAR-T cell therapies have seen significant breakthroughs managing liquid...
The ImmunoScape team is heading to the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco in a few weeks. Our CEO Choon-Peng (Choon) Ng, our Vice President, Discovery Dan MacLeod, and our Senior Director, Business Development Christopher Alfonso will be in...
ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scientific Advisory Board Expertise from award-winning computational biologist, human immunologist and engineer with experience from Yale, NIH, and NIAID will help advance...
ImmunoScape’s Andreas Wilm offers a behind the scenes look at the machine learning models we trained for research published in Cell Press’ Cell Reports – which validated ImmunoScape’s platform by accurately predicting T-cell antigen specificity through...
ImmunoScape Uses Machine Learning to Accurately Predict Antigen Specificity Based on T-Cell Phenotypes in New Peer-Reviewed Research ImmunoScape’s platform accelerates the discovery of efficacious TCR-based therapeutics for solid tumors SAN DIEGO, Calif., and...